Fact CheckerSign in

NCT05516953CompletedPhase 2/3

Baclofen in Preventing Postoperative Nausea and Vomiting After Bariatric Surgery

Clinical Study Evaluating the Efficacy of Baclofen in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy

Source: ClinicalTrials.gov · Last updated 22 Apr 2025

Brief summary (registry, in English)

This study aims to evaluate the possible efficacy of baclofen on postoperative nausea and vomiting in patient with morbid obesity who will undergo laparoscopic sleeve gastrectomy.

Status (registry)
Completed
Phase (registry)
Phase 2/3
Study type
Interventional
Enrollment
100 (actual)
First submitted
24 Aug 2022
Start date
22 Aug 2022
Primary completion date
28 Dec 2024
Lead sponsor
Tanta University
Diseases
Obesity
NCT number
NCT05516953

What you commit to

  • Study type: Interventional · Phase 2/3
  • Participants enrolled: 100
  • From 22 Aug 2022 to the primary completion date, 28 Dec 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with previous procedures for the treatment of obesity.
  • Administration of antiemetic medication or systemic corticosteroids within 24 hours before surgery
  • Patients who experienced vomiting within 24 hours before surgery.

Other illness

  • Patients with psychological or psychiatric disease
  • Patients with history of alcohol or drug abuse.
  • Patients with hypersensitivity or contraindications to any of the drugs used in this study.

Other

  • Patients with BMI \>55 kg/m2.
  • Pregnant females and lactating women.

Who the study is looking for

  • Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥35 kg/m2 with the presence of comorbidity such as hypertension, arthritis, and diabetes.
  • Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥ 40 kg/m2 without comorbidity.
  • Patients fit for anesthesia and surgery.

Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Gastrointestinal and Laparoscopic Surgery Unit, General Surgery Department, Tanta University Hospital.
Coordinator of this site? Confirm its status
TantaEgyptUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.